HKEX Stock Code: 01093
English
|
繁體
|
简体
Home
About Us
Products
News
Competence
Investor Relations
Contact Us
Corporate Profile
Corporate Information
Corporate Culture
Board of Directors
Corporate Governance
Products Overview
Finished Drugs
Bulk Drugs
Press Releases
Strategies
Quality
Research and Development
IR Overview
Financial Reports
CSR Reports
Announcements & Notices
Returns on Share Capital
Circulars
Presentations
Documents on Display
Shareholder Services
Notice(s) of Replacement
of Lost Share Certificates
Financial Calendar
Financial Summary
IR Contacts
Latest News
Oct
08
VOLUNTARY ANNOUNCEMENT - OMALIZUMAB FOR INJECTION OBTAINS MARKETING APPROVAL GRANTED BY NMPA
Oct
08
VOLUNTARY ANNOUNCEMENT - CPO301 RECEIVES FAST TRACK DESIGNATION FROM THE US FDA
Oct
07
VOLUNTARY ANNOUNCEMENT - EXCLUSIVE LICENSE AGREEMENT FOR YS2302018 WITH ASTRAZENECA
/?php echo file_get_contents("https://www.irasia.com/cgi-local/adaptation/listco/hk/cspc/data.cgi?id=cspc&p=data&t=aclp&layout=home&n=3"); ?>
Financial Reports
2024 Interim Report
Highlight - 2024 1H
Revenue
RMB16,284M, +1.3%
Underlying profit attributable to shareholders
RMB3,217M, +1.7%
Reported profit attributable to shareholders
RMB3,020M, +1.8%
Basic earnings per share (reported)
RMB25.51 cents, +2.2%
Basic earnings per share (underlying profit)
RMB27.17 cents, +2.2%
Key Products
Finished drugs
Bulk drugs
NBP (soft capsules)
NBP (injections)
Oulaining (capsules)
Oulaining (lyophilised powder for injections)
Enxi
Duomeisu
Jinyouli
Keaili
Shuluoke
Nuomoling
Weihong
Xinweihong
Xuanning
Encun
Qixiao
Linmeixin
Shuanglexin
Gubang
Gubangjia
Gaoshunsong
Debixin
Qimaite
Antibiotics
Vitamin C
Caffeine